<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04440592</url>
  </required_header>
  <id_info>
    <org_study_id>MT-7117-G02</org_study_id>
    <nct_id>NCT04440592</nct_id>
  </id_info>
  <brief_title>Study to Evaluate Efficacy, Safety, and Tolerability of MT‑7117 in Subjects With Diffuse Cutaneous Systemic Sclerosis</brief_title>
  <official_title>A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate Efficacy, Safety, and Tolerability of MT‑7117 in Subjects With Diffuse Cutaneous Systemic Sclerosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mitsubishi Tanabe Pharma Development America, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mitsubishi Tanabe Pharma Development America, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the efficacy of MT‑7117 treatment in subjects with diffuse cutaneous systemic
      sclerosis (dcSSc) using the American College of Rheumatology Composite Response Index in
      Diffuse Systemic Sclerosis (ACR CRISS) at Week 52
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">July 2020</start_date>
  <completion_date type="Anticipated">November 2022</completion_date>
  <primary_completion_date type="Anticipated">October 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The ACR CRISS composite score (0-1) at Week 52</measure>
    <time_frame>Week 52</time_frame>
    <description>The comparison between MT-7117 treatment group and placebo group will be performed</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Health Assessment Questionnaire Disability Index (HAQ-DI) from baseline up to week 52</measure>
    <time_frame>52 weeks</time_frame>
    <description>To evaluate the efficacy of MT 7117 treatment for up to 52 weeks using the Health Assessment Questionnaire Disability Index (HAQ DI)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in percent predicted forced vital capacity (%pFVC) from baseline up to week 52</measure>
    <time_frame>52 weeks</time_frame>
    <description>To evaluate the efficacy of MT-7117 treatment for up to 52 weeks on pulmonary function as measured by percent predicted forced vital capacity (%pFVC)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Patient Global Assessment from baseline up to week 52</measure>
    <time_frame>52 weeks</time_frame>
    <description>To evaluate the efficacy of MT‑7117 treatment for up to 52 weeks using the Patient Global Assessment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Physician Global Assessment from baseline up to week 52</measure>
    <time_frame>52 weeks</time_frame>
    <description>To evaluate the efficacy of MT‑7117 treatment for up to 52 weeks using the Physician Global Assessment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in modified Rodnan Skin Score (mRSS) from baseline from baseline up to week 52</measure>
    <time_frame>52 weeks</time_frame>
    <description>To evaluate the efficacy of MT-7117 treatment for up to 52 weeks using the modified Rodnan Skin Score (mRSS)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ACR CRISS Score up to Week 39</measure>
    <time_frame>39 weeks</time_frame>
    <description>To evaluate the efficacy of MT 7117 treatment for up to 39 weeks using the ACR CRISS Score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ACR CRISS score responder (CRISS&gt;=0.6) from baseline up to week 52</measure>
    <time_frame>52 weeks</time_frame>
    <description>To evaluate the efficacy of MT-7117 treatment for up to 52 weeks using CRISS Score</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">72</enrollment>
  <condition>Diffuse Cutaneous Systemic Sclerosis</condition>
  <arm_group>
    <arm_group_label>MT-7117</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MT-7117</intervention_name>
    <description>MT-7117</description>
    <arm_group_label>MT-7117</arm_group_label>
    <other_name>Dersimelagon</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Additional screening criteria check may apply for qualification.

        Inclusion Criteria:

          -  Subjects who meet all the following criteria will be considered eligible to
             participate in the study:

               1. Must provide signed and dated informed consent form (ICF) to participate in the
                  study. Subjects must be able to (in the judgment of the Investigator) understand
                  the nature of the study and all risks involved with participation in the study.
                  Subjects must be willing to cooperate and comply with all protocol restrictions
                  and procedures including study visits.

               2. Male or female aged 18 to 75 years inclusive at screening with documented
                  diagnosis of systemic sclerosis (SSc), as defined using the 2013 ACR/European
                  League Against Rheumatism (EULAR) criteria.

               3. Has diffuse cutaneous form of SSc according to Leroy and Medsger's criteria.

               4. Disease duration ≤ 5 years from the first non-Raynaud's phenomenon manifestation.

               5. Has an mRSS of 15 to 45 units at screening and have clinical skin involvement
                  proximal and distal to the elbows, knees, or both or any truncal involvement,
                  with or without face involvement.

               6. If disease duration is &gt; 24 months defined as time from the first non Raynaud
                  phenomenon manifestation, subject must fulfill at least 1 of the criteria listed
                  below that are indicatives of active disease at screening:

                    1. A documentation of new skin involvement, or

                    2. Increase in mRSS ≥ 3 units over the last 6 months, or

                    3. Presence of TFRs or,

                    4. C- reactive protein (CRP) ≥ 6 mg/L, or

                    5. Erythrocyte sedimentation rate ≥ 28 mm/hr, or

                    6. Platelet count ≥ 330 x 10^9/L (330,000/microliter).

                  NOTE: Investigator should exclude all other acute intercurrent illness if
                  subjects fulfilling laboratory criteria (d, e, f) only.

               7. Willing to follow restrictions regarding concomitant medications that are
                  described.

               8. Female subjects who are non-lactating and have a negative urine pregnancy test at
                  baseline visit prior to receiving the first dose of study drug.

               9. Female subjects of childbearing potential and male subjects with partner of
                  child-bearing potential currently using/willing to use 2 effective methods of
                  contraception including barrier method as described.

        Exclusion Criteria:

          -  Subjects will be excluded from the study if any of the following criteria apply:

               1. Has a history or presence of rheumatic autoimmune diseases other than dcSSc
                  unless the dominant features of the disease are dcSSc, as determined by the
                  Investigator.

               2. Has a pulmonary disease with FVC ≤ 50% of predicted or diffusion capacity of the
                  lung for carbon monoxide [DLco] (hemoglobin corrected) ≤ 45% of predicted at time
                  of screening

               3. Has a diagnosis of clinically significant resting pulmonary hypertension (if
                  exceeding estimated right ventricular systolic pressure of &gt; 40 mmHg estimated by
                  transthoracic echocardiography [unless the right heart catheterization is normal
                  within the last 6 months] or mean pulmonary artery pressure &gt; 30 mmHg as measured
                  by right heart catheterization) and requires treatment with more than one oral
                  medication.

               4. Has a cardiac abnormality such as left ventricular failure with ejection fraction
                  &lt; 45%, significant arrhythmia, congestive heart failure (New York Heart
                  Association Class II-IV), unstable angina, uncontrolled hypertension, or
                  symptomatic pericardial effusion at screening.

               5. Has a history of myocardial infarction in the last 26 weeks prior to screening.

               6. Has a history of renal crisis within the past 52 weeks prior to screening.

               7. Has a documented history of chronic kidney disease [ stage 3b-5, an estimated
                  glomerular filtration rate (eGFR) &lt; 45 ml/min at screening], or any episode of
                  acute kidney injury treated with or without dialysis.

               8. Has a presence of clinically significant hepatobiliary disease based on Liver
                  Function Test (LFT) values at screening: e.g. aspartate aminotransferase (AST),
                  alanine aminotransferase (ALT), alkaline phosphatase (ALP) ≥ 3.0 × upper limit of
                  normal (ULN), or total bilirubin &gt; 1.5 × ULN at screening.

               9. Has a history or presence of clinically significant disease not related to SSc
                  [neurologic, renal, endocrinal, gastrointestinal cardiovascular, hepatic,
                  dermatologic, hematological, musculoskeletal, genitourinary, thromboembolic,
                  advanced arteriosclerosis, hyperthyroidism, moderate to severe hypertension,
                  immunologic disease, pulmonary (e.g., uncontrolled asthma, emphysema, chronic
                  obstructive pulmonary disease) or any other disorder] as determined by the
                  Investigator at screening. Conditions deemed not-clinically significant according
                  to the Investigator's discretion are acceptable.

              10. Has a history or presence of psychiatric disease judged to be clinically
                  significant by the Investigator and which may interfere with the study evaluation
                  and/or safety of the subject.

              11. Has any clinically significant disease or laboratory abnormality judged by the
                  Investigator and which may interfere with the study evaluation and/or safety of
                  the subject.

              12. Has a history of positive hepatitis B surface antigen, hepatitis C antibody,
                  except adequately treated hepatitis C virus (HCV) with documentation of sustained
                  virologic response defined as undetectable HCV RNA at least 12 weeks after the
                  end of treatment

              13. Has a history of positive human immunodeficiency virus (HIV)

              14. Has a history of melanoma, familial melanoma (defined as having 2 or more
                  first-degree relatives, such as parent, sibling, and/or child), or presence of
                  melanoma and/or lesions suspicious for melanoma at screening.

              15. Has a presence of squamous cell carcinoma, basal cell carcinoma, or other
                  malignant skin lesions. Any suspicious lesions or nevi will be evaluated. If the
                  suspicious lesion or nevi cannot be resolved through biopsy or excision, the
                  subject will be excluded from the study.

              16. Has history of any other malignancy(ies) in the last 5 years with the exception
                  of cervical carcinoma in situ.

              17. Has a history or anticipated to receive cell-depleting therapy and or bone marrow
                  transplantation during study treatment period.

              18. Has a history within 6 weeks or anticipated to receive ultraviolet (UV)
                  phototherapy during study treatment period.

              19. Treatment of SSc disease with

                    1. Cyclophosphamide, rituximab, or cyclosporine received within 26 weeks prior
                       to randomization.

                    2. Small molecules such as tofacitinib (JAK inhibitor) received within 12 weeks
                       prior to randomization.

                    3. Pirfenidone received within 12 weeks prior to randomization.

                    4. Oral, intravenous, or intramuscular corticosteroids (prednisone &gt; 10 mg/day
                       or equivalent) received within 30 days prior to randomization

                    5. Nintedanib (up to 150 mg 2 times a day [BID]) or with a change in dose
                       within 12 weeks prior to randomization.

                    6. More than 1 of the following immunosuppressant therapy, has changed
                       medication within 12 weeks prior to randomization, or not on a stable dose
                       of the same medication within 30 days prior to randomization.

                  i. Hydroxychloroquine (up to 400 mg/day), or ii. Mycophenolate (up to 3 g/day),
                  or iii. Mycophenolic acid (up to 2.14 g/day), or iv. Methotrexate (up to 25
                  mg/Week), or v. Meflunomide (up to 20 mg/day), or vi. Azathioprine (up to 3
                  mg/kg/day).

              20. Treatment with afamelanotide or other MC1R agonist within 12 weeks before
                  randomization (Visit 2).

              21. Treatment with any drugs or supplements which, in the opinion of the
                  Investigator, may interfere with the objectives of the study or safety of the
                  subject.

              22. Has previously exposed to MT 7117 (this does not include placebo treated
                  subjects).

              23. Has previously treated with any investigational agent within 12 weeks prior to
                  screening OR 5 half-lives of the investigational product (whichever is longer).

              24. Female subjects who are pregnant, lactating, or intending to become pregnant
                  during the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Head of Medical Science</last_name>
    <role>Study Director</role>
    <affiliation>Mitsubishi Tanabe Pharma Development America, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Clinical Trials Information Desk, to prevent miscommunication,</last_name>
    <phone>please email:</phone>
    <email>information@mt-pharma-us.com</email>
  </overall_contact>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>June 17, 2020</study_first_submitted>
  <study_first_submitted_qc>June 17, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">June 19, 2020</study_first_posted>
  <last_update_submitted>June 17, 2020</last_update_submitted>
  <last_update_submitted_qc>June 17, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 19, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Scleroderma, Systemic</mesh_term>
    <mesh_term>Scleroderma, Diffuse</mesh_term>
    <mesh_term>Sclerosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

